Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMC-C103A
- Development stage
- Unknown
- Lead developer
- Immunocore
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
IMC-C103A is an investigational immune mobilizing monoclonal T cell receptor against cancer (ImmTAC®) molecule designed to target MAGE-A4-positive cancers in HLA-A*02:01-positive patients. It functions by redirecting T cells to recognize and destroy tumor cells expressing the MAGE-A4 antigen, a cancer-testis antigen often found in solid tumors. Developed by Immunocore, it is being evaluated for advanced solid tumors that are relapsed, refractory, or intolerant to standard therapies, with administration routes including intravenous and subcutaneous.[1]
02
Targets
CD3 (T-cell surface glycoprotein CD3)MAGE-A4 peptide-HLA-A*02:01 complexMAGEA4 (Melanoma-associated antigen A4)
Beyond the preview
Go deeper on IMC-C103A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMC-C103A.